Estimating antiviral effectiveness against pandemic influenza using household data.
Current estimates of antiviral effectiveness for influenza are based on the existing strains of the virus. Should a pandemic strain emerge, strain-specific estimates will be required as early as possible to ensure that antiviral stockpiles are used optimally and to compare the benefits of using antivirals as prophylaxis or to treat cases. We present a method to measure antiviral effectiveness using early pandemic data on household outbreak sizes, including households that are provided with antivirals for prophylaxis and those provided with antivirals for treatment only. We can assess whether antiviral drugs have a significant impact on susceptibility or on infectivity with the data from approximately 200 to 500 households with a primary case. Fewer households will suffice if the data can be collected before case numbers become high, and estimates are more precise if the study includes data from prophylaxed households and households where no antivirals are provided. Rates of asymptomatic infection and the level of transmissibility of the virus do not affect the accuracy of these estimates greatly, but the pattern of infectivity in the individual strongly influences the estimate of the effect of antivirals on infectivity. An accurate characterization of the infectiousness profile--informed by strain-specific data--is essential for measuring antiviral effectiveness.
Glass
Kathryn
K
National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory 0200, Australia. kathryn.glass@anu.edu.au
Becker
Niels G
NG
D000998:Antiviral Agents / Q000627:therapeutic use*; D003625:Data Collection; D004196:Disease Outbreaks; D005191:Family Characteristics; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology* / Q000635:transmission; D008962:Models, Theoretical; D016896:Treatment Outcome
D000998:Antiviral Agents